Dr. Yan Xing, MD
Medical Oncology (Medical Oncology Physician)
1500 E. Duarte Road
Duarte, CA 91010
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 230
Licensed in California since 2018, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A158622 (first issued 2018; current) -
Internal Medicine Physician
MA license 251165
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- City of Hope Medical Foundation (982 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 230
- Services billed
- 1,460
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 622 | 186 |
| New patient office or other outpatient visit, 60-74 minutes | 61 | 61 |
| Established patient office or other outpatient visit, 30-39 minutes | 38 | 22 |
| Advance care planning, first 30 minutes | 23 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Duarte, CA | 27 |
| Prochlorperazine Maleate Other prescribers in Duarte, CA | 17 |
| Potassium Chloride Other prescribers in Duarte, CA | 15 |
| Mektovi (binimetinib) | 13 |
| Braftovi (encorafenib) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $196 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $125 |
|---|---|
| Immunocore Limited | $37.02 |
| Regeneron Healthcare Solutions, Inc. | $33.81 |
| Food and Beverage | $196 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $553,836 in research payments for these studies, mostly to the institutions running them.
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie Inc. - Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie Inc. · Recruiting · NCT06084481 - Ph 2 Randomized POC Study of PCV in 1L Melanoma
Genentech, Inc. - Study name not reported
Iovance Biotherapeutics, Inc. - Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
Boehringer Ingelheim Pharmaceuticals, Inc. - IOV-EAP-402
Iovance Biotherapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.